Evidence map›Paper›PMID 24892986›Full record

ArticleAnalytical biochemistry2014

Detection of cresyl phosphate-modified butyrylcholinesterase in human plasma for chemical exposure associated with aerotoxic syndrome.

Lawrence M Schopfer, Patrick Masson, Patricia Lamourette, Stéphanie Simon, Oksana Lockridge

Open access · greenAbstract read
In one paragraph

Article in Analytical biochemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 22 citations in OpenAlex.

  1. Prolonged Disability following Re-Exposure after Complete Recovery from Aerotoxic Syndrome: A Case Report.International journal of environmental research and public health · 2023
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Lawrence M SchopferEppley Institute, University of Nebraska Medical Center, Omaha, NE 68198, USA. Electronic address: lmschopf@unmc.edu.
Patrick MassonEppley Institute, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Patricia LamouretteCEA Saclay, iBiTec-S/SPI, Laboratoire d'Etudes et de Recherche en Immunoanalyse, 91191 Gif sur Yvette Cedex, France.
Stéphanie SimonCEA Saclay, iBiTec-S/SPI, Laboratoire d'Etudes et de Recherche en Immunoanalyse, 91191 Gif sur Yvette Cedex, France.
Oksana LockridgeEppley Institute, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Commissariat à l'Énergie Atomique et aux Énergies Alternatives · FRUniversity of Nebraska Medical Center · USNebraska Medical Center · US

Funding

UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Apar Kishor Ganti · 1985 to 2026
$55.0M
NCI NIH HHS P30 CA036727NCI NIH HHS P30CA036727PHS HHS 200-2012-M-53381
6 · The paper itself

Abstract

Flight crews complain of illness following a fume event in aircraft. A chemical in jet engine oil, the neurotoxicant tri-o-cresyl phosphate, after metabolic activation to cresyl saligenin phosphate makes a covalent adduct on butyrylcholinesterase (BChE). We developed a mass spectrometry method for detection of the cresyl phosphate adduct on human BChE as an indicator of exposure. Monoclonal mAb2, whose amino acid sequence is provided, was crosslinked to cyanogen bromide-activated Sepharose 4B and used to immunopurify plasma BChE treated with cresyl saligenin phosphate. BChE was released with acetic acid, digested with pepsin, and analyzed by liquid chromatography-tandem mass spectrometry (LC-MSMS) on the Triple TOF 5600 mass spectrometer. Peptide FGES198AGAAS with an added mass of 170 Da from cresyl phosphate on serine 198 (Ser198) was detected as parent ion 966.4 Da. When characteristic daughter ions were monitored in the MSMS spectrum, the limit of detection was 0.1% cresyl saligenin phosphate inhibited plasma BChE. This corresponds to 2×10(-9) g in 0.5 ml or 23×10(-15) moles of inhibited BChE in 0.5 ml of plasma. In conclusion, a sensitive assay for exposure to tri-o-cresyl phosphate was developed. Laboratories that plan to use this method are cautioned that a positive result gives no proof that tri-o-cresyl phosphate is toxic at low levels.

Indexed as

AircraftAir PollutantsAmino Acid SequenceAntibodies, MonoclonalAntibody SpecificityButyrylcholinesteraseEnvironmental ExposureHumansImmunoassayLimit of DetectionMass SpectrometryMolecular Sequence DataTritolyl PhosphatesAir PollutantsAntibodies, MonoclonalButyrylcholinesterasetri-o-cresyl phosphateTritolyl PhosphatesAerotoxic syndromeButyrylcholinesteraseMass spectrometryMonoclonal antibody mAb2

Identifiers

PMID24892986
PMCPMC4119843
OpenAlexW2069041175

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.